Project Grant R03CA300740
Award Date 6/11/26
Completion Date 5/31/28
Dollars Obligated $156K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Arkansas for Medical Sciences $628,980 under the Cancer Treatment Research program (CFDA 93.395) on May 1, 2026, for a five-year project concluding April 30, 2031. The project, titled "Exploring Host GSK3B-53BP1 Axis in Immune Control of Solid Tumor Progression," focuses on fundamental and applied research to develop improved methods for treating head and neck squamous cell carcinoma (HNSCC)....
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Michigan a $669,278 Project Grant (CFDA 93.395: Cancer Treatment Research) effective June 1, 2026, through May 31, 2031, to develop and validate a novel microbial-based cancer therapy platform. The research focuses on engineering nonpathogenic, tumor-tropic Escherichia coli bacteria to display membrane-anchored immune cytokines, specifically decoy-resistant interleukin-18 (DR-18), to enhance localized...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $1.10M under the Cancer Treatment Research program (CFDA 93.395), effective August 13, 2025, through April 30, 2030. This research project investigates the transcriptional and epigenetic mechanisms controlling CD8+ tumor-infiltrating lymphocytes (TILs), with a focus on understanding how the transcription factor BCL11B regulates critical T...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan a Project Grant totaling $646,920 under the Cancer Treatment Research program (CFDA 93.395), effective March 11, 2026 through February 28, 2031. This award supports novel multi-targeted therapeutic strategies targeting T-cell lymphomas (TCL) and their tumor microenvironment. The research addresses the critical clinical challenge of chemotherapy-resistant TCL disease, for which...
- Federal Grant Award Summary The National Cancer Institute awarded a $646,671 Project Grant to the Regents of the University of Michigan on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research on antibody drug conjugate (ADC) immunotherapeutics. The research will be conducted at the University of Michigan in Ann Arbor through April 30, 2031. This project focuses on identifying novel payloads and optimizing high avidity low affinity (HALA) antibody designs to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University a $702,132 Project Grant on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics research aimed at identifying small molecule modulators of tumor cell-intrinsic immunogenicity in glioblastoma. The three-year research initiative, concluding May 31, 2029, will employ highly multiplex chemical transcriptomic profiling to screen 3,792...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $420,505 Project Grant to the University of California, San Diego for research under the Cancer Treatment Research program (CFDA 93.395) with performance dates from April 1, 2026 to March 31, 2028. The research focuses on elucidating the mechanisms by which Cowpea Mosaic Virus (CPMV) functions as a potent immunological adjuvant and therapeutic agent. The primary deliverables include fundamental research establishing CPMV's...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $399,829 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, for completion by March 31, 2028. This award supports the rational design of next-generation engineered T cells to enhance cancer immunotherapy through structure-informed protein engineering. The research specifically focuses on improving the persistence and efficacy of chimeric antigen receptor (CAR) T...